Technical Analysis for INBX - Inhibrx, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Narrow Range Bar | Range Contraction | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Narrow Range Bar | Range Contraction | -0.17% | |
Oversold Stochastic | Weakness | -0.17% | |
Oversold Stochastic | Weakness | -0.14% | |
Narrow Range Bar | Range Contraction | -1.16% | |
Oversold Stochastic | Weakness | -1.16% | |
Narrow Range Bar | Range Contraction | -0.85% | |
Doji - Bullish? | Reversal | -0.85% | |
Stochastic Reached Oversold | Weakness | -0.85% |
Alert | Time |
---|---|
Possible NR7 | about 11 hours ago |
Possible Inside Day | about 11 hours ago |
Fell Below Previous Day's Low | 4 days ago |
Down 1% | 5 days ago |
Fell Below Previous Day's Low | 5 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 03/04/2024
Inhibrx, Inc. Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a multivalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcomas; and INBRX-105, an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc-fusion protein-based therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency; and INBRX-103, a mAb in Phase 1 clinical trials that targets cluster of differentiation 47. Its preclinical programs include INBRX-106, a sdAb-based hexavalent agonist of OX40 for a range of oncology indications; and INBRX-111, a multi-functional antibody that targets Pseudomonas aeruginosa. The company was founded in 2010 and is headquartered in La Jolla, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Solid Tumors Tumor Clinical Research Clinical Trial Sarcoma Antitrypsin Deficiency Fusion Protein Pseudomonas Clusters Of Differentiation Pseudomonas Aeruginosa
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 39.79 |
52 Week Low | 14.305 |
Average Volume | 783,687 |
200-Day Moving Average | 25.76 |
50-Day Moving Average | 36.63 |
20-Day Moving Average | 36.51 |
10-Day Moving Average | 35.33 |
Average True Range | 0.84 |
RSI (14) | 38.27 |
ADX | 24.68 |
+DI | 16.72 |
-DI | 27.75 |
Chandelier Exit (Long, 3 ATRs) | 37.26 |
Chandelier Exit (Short, 3 ATRs) | 36.78 |
Upper Bollinger Bands | 39.40 |
Lower Bollinger Band | 33.62 |
Percent B (%b) | 0.23 |
BandWidth | 15.85 |
MACD Line | -0.49 |
MACD Signal Line | -0.25 |
MACD Histogram | -0.248 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 35.42 | ||||
Resistance 3 (R3) | 35.46 | 35.34 | 35.34 | ||
Resistance 2 (R2) | 35.34 | 35.22 | 35.32 | 35.31 | |
Resistance 1 (R1) | 35.14 | 35.14 | 35.08 | 35.10 | 35.29 |
Pivot Point | 35.02 | 35.02 | 34.99 | 35.00 | 35.02 |
Support 1 (S1) | 34.82 | 34.90 | 34.76 | 34.78 | 34.59 |
Support 2 (S2) | 34.70 | 34.82 | 34.68 | 34.57 | |
Support 3 (S3) | 34.50 | 34.70 | 34.54 | ||
Support 4 (S4) | 34.46 |